Katarzyna Unrug-Bielawska

Ms. Katarzyna Unrug-Bielawska

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2013 in Veterinary Pathology
Verified
Journal Article
Open access
HSH. Szymanska
H. Szymanska
JLJ. Lechowska-Piskorowska
J. Lechowska-Piskorowska
EKE. Krysiak
E. Krysiak
ASA. Strzalkowska
A. Strzalkowska
KUKatarzyna Unrug-Bielawska
Katarzyna Unrug-Bielawska
MGM. Gajewska
M. Gajewska
The evaluation of spontaneous lesions in classical inbred strains of mice has become increasingly important because genetically engineered mice (GEMs) are created on these backgrounds. Novel inbred strains—genetically diverse from classic strains—are valuable both as a new background for GEM mice and to increase the genetic variation found in laboratory mice. Newly arising spontaneous genetic alterations in commonly used strains may also lead to new and valuable mouse models of disease. This report evaluates gross and histological lesions in relatively new, classic, and rarely explored mouse inbred strains. Pathological lesions of 1273 mice from 12 inbred strains (129S1/SvW, A.CA- H2f/W, AKR/W, BALB/cW, BN/aW, C57BL/6 W, C57BL/10 W, C3H/W, C3H wad/W, CBA/W, DBA/2 W, and WOM/W) are reported. BN/aW, WOM/W, and C3H wad/W are novel inbred strains produced and maintained in the Department of Genetics and Laboratory Animal Breeding at the Center of Oncology, Warsaw, Poland. Both neoplastic and nonneoplastic lesions were examined. The prevalence of lung neoplasms was significantly higher in A.CA- H2f/W (33.3%) and BALB/cW (33.8%) mice ( P < .01). The prevalence of liver neoplasms was significantly higher in the CBA/W strain ( P < .01). Mammary gland neoplasms arose at a greater frequency in C3H/W mice ( P < .01). The occurrence of uterine neoplasms was higher in DBA/W and 129S1/SvW mice. AKR/W and WOM/W mice developed T-cell lymphoblastic lymphoma with high frequency (110/121 [90.9%] and 159/175 [90.9%], respectively) before 1 year of age. The occurrence of nonneoplastic lesions in the kidneys of BN/aW mice was increased ( P < .01).

19 December 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
MCMagdalena Cybulska
Magdalena Cybulska
TOTomasz Olesinski
Tomasz Olesinski
KGKrzysztof Goryca
Krzysztof Goryca
KPKatarzyna Paczkowska
Katarzyna Paczkowska
MSMalgorzata Statkiewicz
Malgorzata Statkiewicz
JOJerzy Ostrowski
Jerzy Ostrowski
Colorectal cancer (CRC) is the second most common cancer in Europe and a leading cause of death worldwide. Patient-derived xenograft (PDX) models maintain complex intratumoral biology and heterogeneity and therefore remain the platform of choice for translational drug discovery. In this study, we implanted 37 primary CRC tumors and five CRC cell lines into NU/J mice to develop xenograft models. Primary tumors and established xenografts were histologically assessed and surveyed for genetic variants and gene expression using a panel of 409 cancer-related genes and RNA-seq, respectively. More than half of CRC tumors (20 out of 37, 54%) developed into a PDX. Histological assessment confirmed that PDX grading, stromal components, inflammation, and budding were consistent with those of the primary tumors. DNA sequencing identified an average of 0.14 variants per gene per sample. The percentage of mutated variants in PDXs increased with successive passages, indicating a decrease in clonal heterogeneity. Gene Ontology analyses of 4180 differentially expressed transcripts (adj. p value < 0.05) revealed overrepresentation of genes involved in cell division and catabolic processes among the transcripts upregulated in PDXs; downregulated transcripts were associated with GO terms related to extracellular matrix organization, immune responses, and angiogenesis. Neither a transcriptome-based consensus molecular subtype (CMS) classifier nor three other predictors reliably matched PDX molecular subtypes with those of the primary tumors. In sum, both genetic and transcriptomic profiles differed between donor tumors and PDXs, likely as a consequence of subclonal evolution at the early phase of xenograft development, making molecular stratification of PDXs challenging.

Verified
Journal Article
Open access
PDF file
AOAnna Orzeł
Anna Orzeł
KUKatarzyna Unrug-Bielawska
Katarzyna Unrug-Bielawska
DFDagmara Filipecka-Tyczka
Dagmara Filipecka-Tyczka
KBKrzysztof Berbeka
Krzysztof Berbeka
NZNatalia Zeber-Lubecka
Natalia Zeber-Lubecka
AKAnna Kajdy
Anna Kajdy
Perinatal hypoxia is a major cause of neurodevelopmental impairment and subsequent motor and cognitive dysfunctions; it is associated with fetal growth restriction and uteroplacental dysfunction during pregnancy. This review aims to present the current knowledge on brain development resulting from perinatal asphyxia, including the causes, symptoms, and means of predicting the degree of brain damage. Furthermore, this review discusses the specificity of brain development in the growth-restricted fetus and how it is replicated and studied in animal models. Finally, this review aims at identifying the least understood and missing molecular pathways of abnormal brain development, especially with respect to potential treatment intervention.

22 March 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
PCPaweł Czarnowski
Paweł Czarnowski
ABAneta Balabas
Aneta Balabas
ZKZbigniew Kułaga
Zbigniew Kułaga
MKMaria Kulecka
Maria Kulecka
KGKrzysztof Goryca
Krzysztof Goryca
JOJerzy Ostrowski
Jerzy Ostrowski
Background: The study investigated the impact of starch degradation products (SDexF) as prebiotics on obesity management in mice and overweight/obese children. Methods: A total of 48 mice on a normal diet (ND) and 48 on a Western diet (WD) were divided into subgroups with or without 5% SDexF supplementation for 28 weeks. In a human study, 100 overweight/obese children were randomly assigned to prebiotic and control groups, consuming fruit and vegetable mousse with or without 10 g of SDexF for 24 weeks. Stool samples were analyzed for microbiota using 16S rRNA gene sequencing, and short-chain fatty acids (SCFA) and amino acids (AA) were assessed. Results: Results showed SDexF slowed weight gain in female mice on both diets but only temporarily in males. It altered bacterial diversity and specific taxa abundances in mouse feces. In humans, SDexF did not influence weight loss or gut microbiota composition, showing minimal changes in individual taxa. The anti-obesity effect observed in mice with WD-induced obesity was not replicated in children undergoing a weight-loss program. Conclusions: SDexF exhibited sex-specific effects in mice but did not impact weight loss or microbiota composition in overweight/obese children.

7 July 2025 in Cancers
Verified
Journal Article
Open access
PDF file
KUKatarzyna Unrug-Bielawska
Katarzyna Unrug-Bielawska
ZSZuzanna Sandowska-Markiewicz
Zuzanna Sandowska-Markiewicz
MPMagdalena Piątkowska
Magdalena Piątkowska
PCPaweł Czarnowski
Paweł Czarnowski
KGKrzysztof Goryca
Krzysztof Goryca
JOJerzy Ostrowski
Jerzy Ostrowski
Background: Symbiotic gut microbiota can enhance cancer therapy efficacy, while treatment-induced dysbiosis may reduce effectiveness or increase toxicity. Our preclinical study compared the anticancer effects and impact on fecal microbiota and metabolites of two water-soluble SN-38 derivatives (BN-MePPR and BN-MOA), with those observed after treatment with Irinotecan, and the FOLFOX regimen in NOD scid gamma mice bearing patient-derived colon adenocarcinoma xenografts (CRC PDX). Methods: Five individual experiments with Irinotecan and its derivatives and eight individual experiments with FOLFOX were conducted using eight CRC PDX models. Chemotherapeutics were administered intraperitoneally 4–5 times at 5-day intervals. Fecal samples were collected before and after treatment. Microbiota composition was analyzed by 16S rRNA gene (V3–V4 regions) sequencing. Mass spectrometry was used to quantify short-chain fatty acids (SCFAs) and amino acids (AAs). Results: All treatments significantly inhibited tumor growth versus controls. However, no significant changes were observed in gut microbiota α- and β-diversity between treated and untreated groups. Tumor progression in controls was associated with increased abundance of Marvinbryantia, Lactobacillus, Ruminococcus, and [Eubacterium] nodatum group. FOLFOX-treated mice showed increased Marvinbryantia, Bacteroides, and Candidatus Arthromitus, and decreased Akkermansia. No distinct taxa changes were found in the Irinotecan or derivative groups. SCFA levels remained unchanged across groups, while BN-MePPR, BN-MOA, and Irinotecan all increased AA concentrations. Conclusions: Contrary to earlier toxicological data, these findings indicate a relatively limited impact of the tested chemotherapeutics on the gut microbiome and metabolome, emphasizing the importance of research method selection in preclinical studies.

Verified
Journal Article
Open access
PDF file
MKMichal Kopczynski
Michal Kopczynski
MSMalgorzata Statkiewicz
Malgorzata Statkiewicz
MCMagdalena Cybulska
Magdalena Cybulska
UKUrszula Kuklinska
Urszula Kuklinska
KUKatarzyna Unrug-Bielawska
Katarzyna Unrug-Bielawska
MMMichal Mikula
Michal Mikula
TNF-related apoptosis-inducing ligand (TRAIL) is a type II transmembrane protein capable of selectively inducing apoptosis in cancer cells by binding to its cognate receptors. Here, we examined the anticancer efficacy of a recently developed chimeric AD-O51.4 protein, a TRAIL fused to the VEGFA-originating peptide. We tested AD-O51.4 protein activity against human colorectal cancer (CRC) models and investigated the resistance mechanism in the non-responsive CRC models. The quantitative comparison of apoptotic activity between AD-O51.4 and the native TRAIL in nine human colorectal cancer cell lines revealed dose-dependent toxicity in seven of them; the immunofluorescence-captured receptor abundance correlated with the extent of apoptosis. AD-O51.4 reduced the growth of CRC patient-derived xenografts (PDXs) with good efficacy. Cell lines that acquired AD-O51.4 resistance showed a significant decrease in surface TRAIL receptor expression and apoptosis-related proteins, including Caspase-8, HSP60, and p53. These results demonstrate the effectiveness of AD-O51.4 protein in CRC preclinical models and identify the potential mechanism underlying acquired resistance. Progression of AD-O51.4 to clinical trials is expected.